Twist Bioscience (NASDAQ:TWST) Upgraded by ValuEngine to “Buy”

ValuEngine upgraded shares of Twist Bioscience (NASDAQ:TWST) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, ValuEngine reports.

A number of other brokerages have also recently commented on TWST. Evercore ISI initiated coverage on shares of Twist Bioscience in a report on Friday, May 31st. They issued an outperform rating and a $26.66 target price on the stock. Zacks Investment Research cut shares of Twist Bioscience from a buy rating to a hold rating in a report on Wednesday, May 8th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $26.55.

Shares of Twist Bioscience stock traded down $2.49 during trading on Thursday, reaching $29.95. The company’s stock had a trading volume of 437,647 shares, compared to its average volume of 220,730. The stock has a 50-day moving average price of $29.34. The company has a market capitalization of $1.10 billion and a price-to-earnings ratio of -1.17. Twist Bioscience has a fifty-two week low of $12.38 and a fifty-two week high of $35.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.27 and a current ratio of 6.51.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Thursday, August 1st. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The firm had revenue of $13.60 million for the quarter, compared to analyst estimates of $12.51 million. As a group, sell-side analysts anticipate that Twist Bioscience will post -3.65 EPS for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in TWST. Emerald Advisers LLC increased its stake in Twist Bioscience by 146.5% in the 2nd quarter. Emerald Advisers LLC now owns 579,601 shares of the company’s stock valued at $16,814,000 after buying an additional 344,463 shares during the period. BlackRock Inc. acquired a new position in Twist Bioscience in the 4th quarter valued at $7,782,000. Emerald Mutual Fund Advisers Trust increased its stake in Twist Bioscience by 156.0% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 524,093 shares of the company’s stock valued at $15,204,000 after buying an additional 319,373 shares during the period. ARK Investment Management LLC acquired a new position in Twist Bioscience in the 2nd quarter valued at $6,202,000. Finally, JPMorgan Chase & Co. increased its stake in Twist Bioscience by 9.7% in the 1st quarter. JPMorgan Chase & Co. now owns 1,050,458 shares of the company’s stock valued at $24,350,000 after buying an additional 93,144 shares during the period. 18.50% of the stock is currently owned by institutional investors.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Read More: What is a Call Option?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.